Dublin, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Systematic Lupus Erythematosus: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering. A shift in the systemic lupus erythematosus (SLE) market is forecast over the next 10 years, as new product approvals drive a movement from traditional off-label treatment to prescribing of approved therapies. This report addresses the following questions: - How has the approval of Benlysta impacted the treatment algorithm and clinical trial design? - What will drive growth in the SLE market over the next 10 years, and which patient groups will be most impacted by new product launches? - What factors have led to the late-phase clinical trial failures that continue to be seen in SLE? - Which clinical attributes will a new drug need to demonstrate in order to compete in this market? Key Topics Covered: FORECAST: SYSTEMIC LUPUS ERYTHEMATOSUS - Executive Summary - Market Overview and Trends - Market Definition and Methodology - anifrolumab - Benlysta SLE (belimumab) - blisibimod - Primary Research Methodology EPIDEMIOLOGY: SYSTEMIC LUPUS ERYTHEMATOSUS - Executive Summary - Sources and Methodology, - Forecast, - Epidemiologist Insight, - Strengths and Limitations MARKETED DRUGS: SYSTEMIC LUPUS ERYTHEMATOSUS - Executive Summary, - Product Overview, - Primary Research Methodology, - Product profile: Benlysta, - Product profile: Off-label: CellCept, - Product profile: Off-label: Rituxan PIPELINE: SYSTEMIC LUPUS ERYTHEMATOSUS - Executive Summary - Clinical Pipeline Overview - Comparator Therapy - Clinical Trial Design - The Future of Disease Treatment - Recently Discontinued Drugs - Primary Research Methodology - Product profile (late stage): Lupuzor - Product profile (late stage): anifrolumab - Product profile (late stage): atacicept - Product profile (late stage): blisibimod For more information about this report visit http://www.researchandmarkets.com/research/xz...atic_lupus Related Topics: Immune Disorders Drugs , Musculoskeletal Disorders Drugs
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716